An open-label safety study of enfuvirtide injection with a needle-free injection device or needle/syringe: The Biojector 2000 open-label safety study (BOSS)

AIDS Research and Human Retroviruses

Volumn 24, Issue 6, 2008, Pages 805-813

  Lalezari, Jacob P ^a,e   Saag, Michael ^b   Walworth, Charles ^c   Larson, Peter ^d  

^a Quest Clinical Research   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Center for Special Immunology   (United States)

^d HOFFMANN LA ROCHE INC   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENFUVIRTIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYST; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG WITHDRAWAL; ECCHYMOSIS; FEMALE; HEMATOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INJECTION SITE BLEEDING; INJECTION SITE CELLULITIS; INJECTION SITE DISCOMFORT; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE NODULE; INJECTION SITE PAIN; INJECTION SITE PARESTHESIA; INJECTION SITE PRURITUS; INJECTION SITE REACTION; LEG ULCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEEDLE; NEEDLE FREE INJECTION DEVICE; OPEN STUDY; PATIENT SATISFACTION; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

ADULT; EQUIPMENT SAFETY; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; INJECTIONS, INTRADERMAL; INJECTIONS, JET; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PATIENT SATISFACTION; PATIENT SELECTION; PEPTIDE FRAGMENTS; QUESTIONNAIRES; SINGLE-BLIND METHOD;

EID: 45849102422     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0251     Document Type: Article

References (27)

1. Poveda E, Briz V, and Soriano V: Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 2005;7:139-147.
2. Lalezari J, Patel IH, Zhang X, et al.: Influence of subcutaneous injection site on the steady-state pharmacokinetics of enfuvirtide (T-20) in HIV-1-infected patients. Clin Virol 2003;28(2):217-222.
3. Raffi F, Katlama C, Saag M, et al.: Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in T-20 versus optimized regimen only (TORO) trials. Clin Infec Dis 2006;42:870-877.
4. Hicks CB, Cahn P, Cooper DA, et al.: Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: An analysis of combined data from two randomised open-label trials. Lancet 2006;368:466-475.
5. Youle M, Staszweski S, Clotet B, et al.: Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: Recent data and consensus recommendations. HIV Clin Trials 2006;7:86-96.
6. Trottier B, Walmsley S, Reynes J, et al.: Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr 2005;40:413-421.
7. Clotet B, Bellos N, Molina JM, et al.: Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet 2007;369:1169-1178.
8. Reynes, J, Arasteh, K, Clotet, B, et al.: TORO: Ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. AIDS Patient Care STDS 2007;21(8):533-543.
9. Steigbigel R, Kumar P, Eron J, et al., for the BENCHMRK-2 Study Group: Results of BENCHMRK-2, a Phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 25-28 February 2007. Abstract 105bLB.
10. True AL, Chiu YY, Demasi RA, Stout R, and Patel I: Pharmacokinetic bioequivalence of enfuvirtide using a needle-free device versus standard needle administration. Pharmacotherapy 2006;26:1679-1686.
11. Harris M, Joy R, Larsen G, et al.: Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector). AIDS 2006;20:719-723.
12. Rice C and Wilantewicz H: Enfuvirtide patient acceptance strategies for managing injection-site reactions. AIDS Read 2006;16:470-474.
13. Professional Instruction Manual: Biojector 2000 Needle Free Injection Management System, 171-0120-01 Rev. D. Bioject Inc., Tualatin, OR, 2005.
14. Harris M, Larsen G, Valyi M, Walker E, and Montaner JS: Transient neuropathy after needle-free injection outside of recommended sites. AIDS 2006;20:784-785.
15. Loutfy M, Harris M, Raboud J, et al.: A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration. HIV Med 2007;8:427-432.
16. Tschida S, Zappa A, and Godwin M: An ongoing nonrandomized large prospective evaluation of alternative injection devices (Biojector B2000, standard needles/syringes, or insulin needles/syringes) for enfuvirtide (ENF) in a national community-based specialty pharmacy. XVI International AIDS Conference, Toronto, Ontario, Canada, August 13-18, 2006. Abstract TUPE0147.
17. Myers SA, Selim AA, McDaniel MA, et al.: A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. Antiviral Ther 2006;11:935-939.
18. Gottlieb M, True A, Evans R, et al.: Needle-free administration of enfuvirtide significantly reduces incidence of painful injection site reactions: Results from a single blind, randomized, controlled study. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 27-30 September 2006. Abstract H-1905b.
19. Hammer SM, Saag MS, Schechter M, et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006;296:827-843.
20. Nelson M, Arasteh K, Clotet B, et al.: Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr 2005;40:404-412.
21. Lazzarin A, Clotet B, Cooper D, et al.: Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003;348:2186-2195.
22. Lalezari JP, Henry K, O'Hearn M, et al.: Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175-2185.
23. Foy K and Juethner SN: Enfuvirtide (T-20): Potentials and challenges. J Assoc Nurses AIDS Care 2004;15:65-71.
24. Shalit P, True A, and Thommes JA: Quality of life and tolerability after administration of enfuvirtide with a thin-walled needle: QUALITE Study. HIV Clin Trials 2007;8:24-35.
25. Stout RR, Gutierrez MJ, Roffman M, et al.: Subcutaneous injections with a single-use, pre-filled, disposable needle-free injection device or needle and syringe: Comparative evaluation of efficacy and acceptability. Drug Delivery Tech 2004;4:48-52.
26. Gottlieb M, Thommes JA, and the WAND Study Group. Safety, tolerability and pharmacokinetics of enfuvirtide administered in a single-blind, randomized 4-week crossover trial. Antiviral Res (in press).
27. Harris M, Larsen G, Valyi M, Walker E, and Montaner JS: Transient neuropathy after needle-free injection outside of recommended sites. AIDS 2006;20:784-785.